Subgroups according to BASDAI/ASDAS category (baseline)

Frontiers Correlation Between Chronic Pain Acceptance and Clinical Variables in Ankylosing Spondylitis and Its Prediction Role for Biologics Treatment

Frontiers The BASDAI Cut-Off for Disease Activity Corresponding to the ASDAS Scores in a Taiwanese Cohort of Ankylosing Spondylitis

Frontiers The BASDAI Cut-Off for Disease Activity Corresponding to the ASDAS Scores in a Taiwanese Cohort of Ankylosing Spondylitis

Biologics Targeting, Ankylosing Spondylitis

ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapy

Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study - Roberta Ramonda, Mariagrazia Lorenzin, Maria Sole Chimenti, Salvatore D'Angelo, Antonio Marchesoni, Carlo Salvarani, Ennio Lubrano

Frontiers Targeted Therapies in Axial Psoriatic Arthritis

Standardized ASDAS vs standardized SASDAS for (A) baseline pooled data

Refining the Focus: A New Look at Spondylitis

Comparison of (A) ASDAS vs SASDAS in their capacity to each

Genetic and Molecular Distinctions Between Axial Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: Post Hoc Analyses from Four Phase 3 Clinical Trials

NNTs vs. placebo for various thresholds of improvement in BASDAI from